|
促黄体激素释放激素类似物与低剂量炔诺酮联合治疗子宫内膜异位症的疗效与安全性 |
| |
张绍芬 叶国春 陈行 方芳 张剑峰 朱关珍
【摘要】 目的 了解国产促黄体激素释放激素类似物（LHRH-a）与低剂量炔诺酮联合治疗子宫内膜异位症（内异症）的疗效及安全性。方法 将77例内异症患者随机分为两组，A组36例，采用LHRH-a 150 μg每日肌内注射（肌注）+炔诺酮2.5 mg每日口服治疗；B组41例，单独应用LHRH-a肌注，疗程3～6个月。观察治疗前后症状、体征、肝、肾功能、血脂代谢、骨代谢生化指标及右侧胫骨超声速度（SOS）变化。结果 A组总主观症状评分于治疗3个月后下降了82%，6个月后下降了94%，内异症病灶于3个月后缩小了34%，6个月后缩小了61%(与治疗前比较，P<0.01)。B组总主观症状评分于3、6个月后分别下降了77%、90%，内异症病灶分别缩小了37%、38%（P<0.01）。肝、肾功能、空腹血糖均在正常范围。B组血甘油三酯（TG）、载脂蛋白A（ApoA）、血钙、磷、碱性磷酸酶等于治疗后显著升高。B组TG于治疗3个月后、ApoA于治疗6个月后比A组明显升高（P<0.05，P<0.01）；血钙于治疗3个月后、血磷于治疗6个月后、血碱性磷酸酶于治疗3、6个月后也比A组明显升高（P<0.05，P<0.05，P<0.001，P<0.01）。SOS在治疗前后及组间均无显著性改变。A组潮热等副反应发生率为14％，B组为41％（P<0.01）。A组与B组阴道出血率为18%、38％。结论 国产LHRH-a联合低剂量炔诺酮可有效治疗内异症，并能减轻低雌激素症状，降低出血率，减缓骨转换。
【关键词】 促性腺素释放激素；子宫内膜异位症；炔诺酮
The Efficacy and Safety of Domestic Luteinizing Hormone-releasing Hormone Analogue and Low-dose Norethindrone “Add-back” Therapy in the Treatment of Endometriosis
ZHANG Shaofen, YE Guochun, CHEN Hang, et al.
（Department of Gynecology, The Obstetrics and Gynecology Hospital of Shanghai Medical University, Shanghai 200011， China）
【Abstract】 Objective To study the efficacy and safety of combining domestic luteinizing hormone-releasing hormone analogue(LHRH-a) with low-dose norethindrone in the treatment of endometriosis. Methods Seventy-seven women with endometriosis were randomized into one of the following two groups. Group A (n=36) were treated with LHRH-a (150 μg/d, i.m.) plus norethindrone (2.5 mg/d, p.o.) and group B (n=41) received only LHRH-a (150 μg/d, i.m.) for 3 to 6 months. Symptoms and signs were recorded before and after the treatment. Liver and renal functions, lipid and bone metabolism and speed of sound (SOS) in the tibia were also examined at the same time. All data were analyzed using paired and grouped Student′s t-tests. Results Total subjective symptom scores of group A showed 82% decrease at 3 months and 94% at 6 months of treatment [1] [2] [3] 下一页
上一个医学论文： 超大剂量化学药物和外周血干细胞移植治疗晚期妇科恶性肿瘤5例分析
下一个医学论文： 助产工作中潜在不安全因素管理措施
|
|
|
|
|
|
|
您现在的位置： 绿色健康网 >> 医学论文 >> 妇产科论文 >> 正文